Incidence and Factors Associated with Acne in Transgender Adolescents on Testosterone: A Retrospective Cohort Study.
Endocrine Practice 2023 March 7
OBJECTIVE: This retrospective cohort study aimed to assess incidence and predictors of acne among transgender adolescents receiving testosterone.
MATERIALS AND METHODS: We analyzed records of patients aged <18 years, assigned female at birth seen at Children's Healthcare of Atlanta Pediatric Endocrinology clinic for testosterone initiation between 1/1/2000-1/1/2019, with at least 1-year follow-up documented. Bivariable analyses to determine association of clinical and demographic factors with new acne diagnosis were calculated.
RESULTS: Of 60 patients, 46 (77%) did not have baseline acne. 25 of those 46 patients developed acne (54%) within 1-year of testosterone initiation. Overall incidence proportion was 70% at 2-years; patients who used progestin prior to or during follow up were more likely to develop acne than non-users (92% vs 33%, p<0.001).
CONCLUSION: Transgender adolescents starting testosterone, particularly those taking progestin, should be monitored for acne development, and treated proactively by hormone providers and dermatologists.
MATERIALS AND METHODS: We analyzed records of patients aged <18 years, assigned female at birth seen at Children's Healthcare of Atlanta Pediatric Endocrinology clinic for testosterone initiation between 1/1/2000-1/1/2019, with at least 1-year follow-up documented. Bivariable analyses to determine association of clinical and demographic factors with new acne diagnosis were calculated.
RESULTS: Of 60 patients, 46 (77%) did not have baseline acne. 25 of those 46 patients developed acne (54%) within 1-year of testosterone initiation. Overall incidence proportion was 70% at 2-years; patients who used progestin prior to or during follow up were more likely to develop acne than non-users (92% vs 33%, p<0.001).
CONCLUSION: Transgender adolescents starting testosterone, particularly those taking progestin, should be monitored for acne development, and treated proactively by hormone providers and dermatologists.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app